{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=21-hydroxylase+Deficiency",
    "query": {
      "condition": "21-hydroxylase Deficiency"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 80,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=21-hydroxylase+Deficiency&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:22:31.026Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04075149",
      "title": "Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Puberty Disorders",
        "Ovulation Disorder"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "19 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 19 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2019-12-18",
      "completion_date": "2024-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-27",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075149"
    },
    {
      "nct_id": "NCT01735617",
      "title": "Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endocrine Disease",
        "Adrenal Insufficiency",
        "Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Hydrocortisone Modified Release Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine UK Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-17",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735617"
    },
    {
      "nct_id": "NCT03252223",
      "title": "Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Healthy",
        "Anovulation",
        "Hyperandrogenism"
      ],
      "interventions": [
        {
          "name": "Recombinant Follicle Stimulating Hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "37 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 37 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2017-10-02",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03252223"
    },
    {
      "nct_id": "NCT05669950",
      "title": "A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Lu AG13909",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-12-19",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05669950"
    },
    {
      "nct_id": "NCT06712823",
      "title": "An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia",
        "Classic Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "atumelnant (CRN04894)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crinetics Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-02-25",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Morehead City, North Carolina",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712823"
    },
    {
      "nct_id": "NCT00001521",
      "title": "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia (CAH)"
      ],
      "interventions": [
        {
          "name": "Fludrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Testolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 66,
      "start_date": "1995-06-08",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001521"
    },
    {
      "nct_id": "NCT02155933",
      "title": "Assessment of Day-night Secretion of Progesterone and LH Across Puberty",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Puberty",
        "Hyperandrogenism"
      ],
      "interventions": [
        {
          "name": "Blood sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "7 Years to 17 Years · Female only"
      },
      "enrollment_count": 75,
      "start_date": "2008-07-10",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2023-11-02",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02155933"
    },
    {
      "nct_id": "NCT01495910",
      "title": "A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "21-hydroxylase Deficiency"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2011-12",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495910"
    },
    {
      "nct_id": "NCT07247058",
      "title": "Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Mild Autonomous Cortisol Secretion (MACS)"
      ],
      "interventions": [
        {
          "name": "Osilodrostat (Isturisa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2026-02-02",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07247058"
    },
    {
      "nct_id": "NCT04490915",
      "title": "Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Crinecerfont",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2020-12-16",
      "completion_date": "2027-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-11T04:22:31.026Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04490915"
    }
  ]
}